This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Cosentyx
  • /
  • Plaque Psoriasis Efficacy and Safety With Secukinu...
Clinical trial

Plaque Psoriasis Efficacy and Safety With Secukinumab (OPTIMISE)

Read time: 2 mins
Last updated:1st Jan 2015
Identifier: NCT02409667
To demonstrate in the patient pool of PASI 90 responders at Week 24 that secukinumab 300 mg s.c. when administered at a longer dosing interval is non-inferior to secukinumab 300 mg s.c. every 4 weeks treatment with respect to maintaining a PASI 90 response rate at Week 52.


Category Value
Date last updated at source 2016-08-16
Study type(s) Interventional
Expected enrolment 1580
Study start date 2015-01-01
Estimated primary completion date 2017-05-01

View full details